BLOG
Divis Q4FY22 Review: Custom synthesis drives revenues, margins
What’s Buzzing:
Divi's Laboratories' quarterly performance was a significant beat vis-à-vis I-direct and consensus estimates on the back of another strong quarter from custom synthesis.
Context:
Revenues grew 41% YoY to Rs 2518 crore (I-direct estimate: Rs 2302 crore). EBITDA margins improved 380 bps YoY to 43.9% (I-direct estimates of 42.4%), mainly due to lower employee and other expenditure offsetting minor dip in gross margins (down 79 bps YoY to 66.7%). Subsequently, EBITDA grew 54% YoY to Rs 1104 crore (I-direct estimate: Rs 976 crore). Net profit grew 78% YoY to Rs 895 crore (I-direct estimate: Rs 795 crore).
Our perspective:
Divi's FY22 revenue mix was Generics – 41% and Custom Synthesis – 59%. While Custom Synthesis benefited due to significant contribution from Covid opportunity execution for global customer (up 126% YoY in Q4) there was some pressure on generics APIs (down 19% YoY in Q4). Quarterly gyrations notwithstanding, Divi’s USP is fungible multi-purpose blocks and capability of altering production as per client’s requirements. Generics business is likely to take six months for normalisation but with six identified growth areas- 1) Established generics, 2) Existing generics, 3) New generics, 4) Sartan APIs, 5) Contrast Media, 6) Custom Synthesis, the company has well set growth plans which can overcome slowdown in a particular segment. Additionally, with ~US$20 billion opportunity of APIs going off-patent over FY23-25, Divi’s is augmenting capacities with capex plans of Rs 2000-3000 crore over the next two to three years. The company remains a quintessential play on the Indian API/CRAMs segment with its product offerings and execution prowess.
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Related content
Blogs
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Video
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.